Anti Androgen Monotherapy Market
According to Intent Market Research, the Anti-Androgen Monotherapy Market is expected to grow from USD 4.8 Billion in 2024-e at a CAGR of 10.8% to touch USD 8.9 Billion by 2030. The Anti-Androgen Monotherapy Market is dominated by key players such as Bayer AG, AbbVie Inc., Ipsen, Johnson & Johnson, Ferring Pharmaceuticals, and Merck & Co., Inc.